Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Hepatocyte Growth Factor and Cardiovascular Autonomic Function

This study has been completed.
Information provided by:
Oita Red Cross Hospital Identifier:
First received: May 23, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted
In this study, we tested the hypothesis that elevated HGF is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients not receiving insulin treatment.

Type-2 Diabetes

Study Type: Observational
Study Design: Allocation: Random Sample
Time Perspective: Cross-Sectional
Time Perspective: Retrospective

Further study details as provided by Oita Red Cross Hospital:


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Type-2 diabetes

Exclusion Criteria:

  • Type-1 diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00478127

Sponsors and Collaborators
Oita Red Cross Hospital
Principal Investigator: Futoshi Anan Oita Red Cross Hospital
  More Information Identifier: NCT00478127     History of Changes
Other Study ID Numbers: AO-272 
Study First Received: May 23, 2007
Last Updated: May 23, 2007
Health Authority: Japan: Institutional Review Board processed this record on October 25, 2016